We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

The Norwegian Pancreas Transplantation (PTx) Study (PTx)

This study is currently recruiting participants.
Verified October 2013 by Oslo University Hospital
ClinicalTrials.gov Identifier:
First Posted: October 8, 2013
Last Update Posted: October 10, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Aarhus University Hospital
Information provided by (Responsible Party):
Oslo University Hospital

Several studies have shown acceptable results after Pancreas Transplantation (PTx) by substituting ATG with basiliximab, which is considered to convey a considerably lower number of adverse events. However, our experiences with ATG in PTx (introduced in 2004) are good, and our presumably gentle way of administrating the drug - directed by T-cell counts - is in fact unique. The potential advantages of reducing the overall corticosteroid (CS) load is obvious, as CS is a well-known pro-diabetic agent and causes severe long term adverse effects.

On this background, the investigators have very recently reduced our CS dosing (in the routine protocol) to a level corresponding to our Kidney Tx protocol (valid since 2009).

Thus, the investigators intend to prospectively investigate a single PTx cohort with the reduced CS immunosuppressive protocol by an observational study design, and compare with previous (historical) cohorts, who have received high dose CS.

Study hypotheses: i) Low-dose CS is as effective as high-dose corticosteroids with regards to efficacy/rejections; ii) The rate of surgical and infectious complications will be similar or lower in the low-dose group; iii) PTx rejection surveillance by DD (duodenoduodeno-stomy) and EUSPB (Endoscopic Ultra-Sound guided Pancreas Biopsies) is superior to traditional rejection surveillance; iv) Patient and graft survival is similar in the two groups

Condition Phase
Diabetes Mellitus Pancreas Transplantation Allograft Rejection Surgical Complication Nec Allograft Biopsies Phase 4

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Official Title: A Prospective, Observational Study in Pancreatic Allograft Recipients: The Effect of Risk Factors, Immunosuppressive Level and the Benefits of Scheduled Biopsies - on Surgical Complications, Rejections and Graft Survival

Resource links provided by NLM:

Further study details as provided by Oslo University Hospital:

Primary Outcome Measures:
  • Incidence of acute rejection episodes after pancreas- or pancreas- + kidney- transplantation [ Time Frame: 5 years ]

    Compare the incidence of acute rejection episodes at 6, 12, 36 and 60 months after pancreas transplantation, between our single prospective cohort with lower CS vs a historic, retrospective control group (PTx performed during 2011-2013). The incidence of rejection is defined as the fraction of patients in which rejections episodes (one or more) have been proven by biopsies. For SPK rejection in either organ, pancreas or kidney, counts.

    Furthermore, we will compare the number and severity of rejection episodes in the pancreas allograft to the ones occurring in the kidney allograft (SPK), and the ones diagnosed by the duodenal segment biopsies.

  • Surgical complications [ Time Frame: 5 years ]
    Compare the incidence of surgical complications, involving reoperations and reinterventions, between the prospective study cohort and retrospective control group.

Secondary Outcome Measures:
  • Graft survival [ Time Frame: 5 years ]
    Record kidney (and pancreas) graft survival (SPK) 12, 36 and 60 months post-Tx

  • Patient survival [ Time Frame: 5 years ]
    Compare patient survival at 12, 36 and 60 months post-Tx.

  • Non-surgical complications [ Time Frame: 5 years ]
    Compare the incidence of non-surgical complications; infections, cardial complications, pulmonary complications and neurological complications.

Other Outcome Measures:
  • Immunological analyses in blood samples [ Time Frame: 5 years ]

    Blood samples will be obtained at the time of transplantation and later scheduled time points:

    • Study of immune cell activation (CD25, FOXP3, CD4, CD3, CD8, CD45RO, perforin, granzyme A/B, etc) and cytokines (IL-2, TNF-a, IFN-g, IL-10, IL-12 etc).
    • Compare biomarkers in serum, indicative of acute rejection, by at least weekly blood sampling post-Tx (RNA microarray on a series of genes related to rejection, quantitative PCR on selected genes)
    • Study Pancreas Auto-antibodies

  • Immunological analyses in allograft biopsies [ Time Frame: 12 mts ]

    Scheduled biopsies will be taken at 3 wks, 6 wks and 12 mts post-Tx; as well as indication biopsies, simultaneously from these four transplant/organ sources: Pancreas-Tx (P); Kidney-Tx (K); Duodenal segment of pancreas-Tx (tD); Native Duodenum (nD; serves as control)

    • Immunohistochemistry on immunologic markers (CD25, FOXP3, CD4, CD3, CD8, CD45RO, perforin, granzyme A/B, etc)
    • DNA/RNA- analyses on immunologic markers; PCR, RNA microarray

  • Endoscopic mucosal imaging and ultrasound [ Time Frame: 12 mts ]
    • During upper endoscopy for scheduled biopsies (at 3 wks, 6 wks and 12 mts post-Tx), pictures of the transplant duodenal mucosa will be taken. The mucosal images will be rated regarding rubor, edema villous atrophy etc. and compared to biopsy rejection scores.
    • Endoscopic ultrasound (EUS) will be used during biopsying of the pancreas. EUS images will be sampled and stored, for comparative analysis. The EUS analysis will mainly involve circulatory parameters.

  • Donor and recipient baseline characteristics [ Time Frame: 5 years ]

    We will investigate relationships between the below mentioned donor/recipient characteristics and graft survival/surgical complications/non-surgical complications:

    • Donor age
    • Donor gender
    • Donor BMI
    • Recipient age
    • Recipient gender
    • Recipient BMI
    • Recipient PRA (Panel Reactive Antibody) status
    • Recipient comorbidity status; particularly cardiovascular status

  • Non-immunological rejection markers [ Time Frame: 12 mts ]

    The following analyses will be performed and correlated to rejection, functional parameters (glucose levels/need for insulin (P) and creatinine (K)), and graft survival. By daily blood samples during the first 10 days, 3 times a week until week 10, at 3 & 12 mts, and on indication.

    • Amylase (pancreas specific amylase)
    • Lipase
    • CRP
    • Amylase/Lipase/CRP combined parameter
    • C-peptide and C-peptide/Glucose/Creatinine-ratio (C-peptide : Glucose x Creatinine)
    • In addition, amylase in drainage fluid will be measured daily, until the drains are removed (usually at day 4-8 post-Tx).

Biospecimen Retention:   Samples With DNA

Blood samples will be obtained at the time of Tx and later scheduled time points to:

  • Study of immune cell activation (CD25, FOXP3, CD4, CD3, CD8, CD45RO, perforin, granzyme A/B, etc) and cytokines (IL-2, IL-12 etc)
  • Compare biomarkers in serum, indicative of acute rejection; RNA microarray on a series of genes related to rejection, quantitative PCR on selected genes)

Scheduled biopsies will be taken according to our present routine protocol at 3 wks, 6 wks and 12 mts post-Tx, as well as indication biopsies; simultaneosly from these four transplant/organ sources:

Pancreas-Tx (P); Kidney-Tx (K); Duodenal segment of pancreas-Tx (tD; Native Duodenum (control)

Histological and molecular evaluations will involve:

  • Rejection histology scores
  • Immunoshistochemistry on immunologic markers (CD25, FOXP3, CD4, CD3, CD8, CD45RO, perforin, granzyme A/B, etc)
  • DNA/RNA analyses on immunologic markers: PCR, RNA microarray

Estimated Enrollment: 80
Study Start Date: September 2013
Estimated Study Completion Date: October 2020
Estimated Primary Completion Date: October 2020 (Final data collection date for primary outcome measure)
Pancreas-Tx recipients; single cohort
This is a prospective, single cohort observational study, aimed at using a historical control group as comparison. It will be conducted at our single, national centre for organ transplantation in Oslo. All pancreas recipients > 18 years of age, who fulfill the inclusion criteria, will prior to transplantation be asked for inclusion.

  Show Detailed Description


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

This study will be conducted at our single, national centre for organ transplantation in Oslo.

All consecutive Pancreas-Tx recipients during 2-3 years are planned to be enrolled, with an intented number of 60-80 patients. The study will continue until all patients have completed a minimum of 60 months of follow-up or have discontinued participation in the study.


Inclusion Criteria:

  • Age ≥18 years
  • Patients who receive a primary or secondary pancreas transplant, with or without a simultaneous kidney transplant (SPK).
  • Women who are of childbearing potential must have a negative serum pregnancy test at baseline.
  • Operability has to be ascertained by preoperative examination, performed by nephrologist, transplant surgeon and anaesthesiologist.
  • Signed and dated informed consent form.

Exclusion Criteria:

  • Evidence of systemic infection
  • Presence of unstable cardiovascular disease.
  • Malignancy < 5 years prior to entry into the trial (with the exception of adequately treated basal cell or squamous cell carcinomas of the skin).
  • Panel-reactive antibodies (PRA) > 20% or the presence of donor-specific antigens (DSA).
  • Any positive test for HBV, HBC or HIV.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01957696

Contact: Ole M Øyen, MD, PhD +47 92264777 ole.oyen@ous-hf.no
Contact: Rune Horneland, MD +47 91177121 rune.horneland@ous-hf.no

Oslo University Hospital Recruiting
Oslo, Norway, 0027
Contact: Ole M Øyen, MD, PhD    +47 92264777    ole.oyen@ous-hf.no   
Contact: Rune Horneland, MD    +47 91177121    rune.horneland@ous-hf.no   
Principal Investigator: Ole M Øyen, MD, PhD         
Sponsors and Collaborators
Oslo University Hospital
Aarhus University Hospital
Principal Investigator: Ole M Øyen, MD, PhD Oslo University Hospital
  More Information

Kelly WD, Lillehei RC, Merkel FK, Idezuki Y, Goetz FC. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery. 1967 Jun;61(6):827-37.
Gruessner AC. 2011 update on pancreas transplantation: comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry (IPTR). Rev Diabet Stud. 2011 Spring;8(1):6-16. doi: 10.1900/RDS.2011.8.6. Epub 2011 May 10. Review.
Sutherland DE, Gruessner RW, Dunn DL, Matas AJ, Humar A, Kandaswamy R, Mauer SM, Kennedy WR, Goetz FC, Robertson RP, Gruessner AC, Najarian JS. Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg. 2001 Apr;233(4):463-501. Review.
Sollinger HW, Odorico JS, Becker YT, D'Alessandro AM, Pirsch JD. One thousand simultaneous pancreas-kidney transplants at a single center with 22-year follow-up. Ann Surg. 2009 Oct;250(4):618-30. doi: 10.1097/SLA.0b013e3181b76d2b.
Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999 Dec 2;341(23):1725-30.
Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D, Klarenbach S, Gill J. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011 Oct;11(10):2093-109. doi: 10.1111/j.1600-6143.2011.03686.x. Epub 2011 Aug 30.
Brekke IB. Indications and results of pancreatic transplantation: the Oslo experience 1983-1990. Diabetologia. 1991 Aug;34 Suppl 1:S18-20.
Bentdal OH, Fauchald P, Brekke IB, Holdaas H, Hartmann A. Rehabilitation and quality of life in diabetic patients after successful pancreas-kidney transplantation. Diabetologia. 1991 Aug;34 Suppl 1:S158-9.
Brekke IB. Duct-drained versus duct-occluded pancreatic grafts: a personal view. Transpl Int. 1993 Mar;6(2):116-20. Review.
Brekke IB, Bentdal O, Pfeffer P, Lien B, Sødal G, Holdaas H, Fauchald P, Jervell J. [Pancreas transplantation. A 10-year material]. Tidsskr Nor Laegeforen. 1995 Feb 28;115(6):703-5. Norwegian.
Brekke IB. [Pancreas transplantation--a review]. Tidsskr Nor Laegeforen. 1999 Sep 20;119(22):3305-9. Review. Norwegian.
Lindahl JP, Hartmann A, Horneland R, Holdaas H, Reisæter AV, Midtvedt K, Leivestad T, Oyen O, Jenssen T. Improved patient survival with simultaneous pancreas and kidney transplantation in recipients with diabetic end-stage renal disease. Diabetologia. 2013 Jun;56(6):1364-71. doi: 10.1007/s00125-013-2888-y. Epub 2013 Apr 3.
Margreiter C, Aigner F, Resch T, Berenji AK, Oberhuber R, Sucher R, Profanter C, Veits L, Öllinger R, Margreiter R, Pratschke J, Mark W. Enteroscopic biopsies in the management of pancreas transplants: a proof of concept study for a novel monitoring tool. Transplantation. 2012 Jan 27;93(2):207-13. doi: 10.1097/TP.0b013e31823cf953.
Rogers J, Farney AC, Al-Geizawi S, Iskandar SS, Doares W, Gautreaux MD, Hart L, Kaczmorski S, Reeves-Daniel A, Winfrey S, Ghanta M, Adams PL, Stratta RJ. Pancreas transplantation: lessons learned from a decade of experience at Wake Forest Baptist Medical Center. Rev Diabet Stud. 2011 Spring;8(1):17-27. doi: 10.1900/RDS.2011.8.17. Epub 2011 May 10. Review.
Meier-Kriesche HU, Li S, Gruessner RW, Fung JJ, Bustami RT, Barr ML, Leichtman AB. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant. 2006;6(5 Pt 2):1111-31.
Schulz T, Flecken M, Kapischke M, Busing M. Single-shot antithymocyte globuline and daclizumab induction in simultaneous pancreas and kidney transplant recipient: three-year results. Transplant Proc. 2005 May;37(4):1818-20.
Boggi U, Vistoli F, Amorese G, Giannarelli R, Coppelli A, Mariotti R, Rondinini L, Barsotti M, Piaggesi A, Tedeschi A, Signori S, De Lio N, Occhipinti M, Mangione E, Cantarovich D, Del Prato S, Mosca F, Marchetti P. Results of pancreas transplantation alone with special attention to native kidney function and proteinuria in type 1 diabetes patients. Rev Diabet Stud. 2011 Summer;8(2):259-67. doi: 10.1900/RDS.2011.8.259. Epub 2011 Aug 10.
Ollinger R, Margreiter C, Bösmüller C, Weissenbacher A, Frank F, Schneeberger S, Mark W, Margreiter R, Pratschke J. Evolution of pancreas transplantation: long-term results and perspectives from a high-volume center. Ann Surg. 2012 Nov;256(5):780-6; discussion 786-7. doi: 10.1097/SLA.0b013e31827381a8. Erratum in: Ann Surg. 2013 Mar;257(3):570.
Wu T, Abu-Elmagd K, Bond G, Nalesnik MA, Randhawa P, Demetris AJ. A schema for histologic grading of small intestine allograft acute rejection. Transplantation. 2003 Apr 27;75(8):1241-8.
Li L, Khatri P, Sigdel TK, Tran T, Ying L, Vitalone MJ, Chen A, Hsieh S, Dai H, Zhang M, Naesens M, Zarkhin V, Sansanwal P, Chen R, Mindrinos M, Xiao W, Benfield M, Ettenger RB, Dharnidharka V, Mathias R, Portale A, McDonald R, Harmon W, Kershaw D, Vehaskari VM, Kamil E, Baluarte HJ, Warady B, Davis R, Butte AJ, Salvatierra O, Sarwal MM. A peripheral blood diagnostic test for acute rejection in renal transplantation. Am J Transplant. 2012 Oct;12(10):2710-8. doi: 10.1111/j.1600-6143.2012.04253.x.
Allison SJ. Transplantation: Biomarkers in peripheral blood detect acute rejection. Nat Rev Nephrol. 2012 Dec;8(12):681. doi: 10.1038/nrneph.2012.227. Epub 2012 Oct 16.

Responsible Party: Oslo University Hospital
ClinicalTrials.gov Identifier: NCT01957696     History of Changes
Other Study ID Numbers: OUS-PTx-01
First Submitted: September 30, 2013
First Posted: October 8, 2013
Last Update Posted: October 10, 2013
Last Verified: October 2013

Keywords provided by Oslo University Hospital:
Diabetes mellitus
Pancreas transplantation
Surgical complications
Allograft biopsies
Immunological analyses
Pancreas graft survival

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Gastrointestinal Agents

To Top